1,050 Shares in Insulet Co. (NASDAQ:PODD) Bought by Everence Capital Management Inc.

Everence Capital Management Inc. acquired a new stake in shares of Insulet Co. (NASDAQ:PODD) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,050 shares of the medical instruments supplier’s stock, valued at approximately $274,000.

Several other hedge funds have also made changes to their positions in PODD. GAMMA Investing LLC grew its holdings in shares of Insulet by 44.0% during the fourth quarter. GAMMA Investing LLC now owns 2,424 shares of the medical instruments supplier’s stock valued at $633,000 after buying an additional 741 shares in the last quarter. Versant Capital Management Inc boosted its position in Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock worth $80,000 after acquiring an additional 157 shares during the period. Principal Financial Group Inc. grew its stake in Insulet by 4.0% during the 3rd quarter. Principal Financial Group Inc. now owns 86,210 shares of the medical instruments supplier’s stock valued at $20,065,000 after acquiring an additional 3,355 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in shares of Insulet in the 3rd quarter valued at about $202,000. Finally, Synovus Financial Corp lifted its position in shares of Insulet by 36.1% in the third quarter. Synovus Financial Corp now owns 2,929 shares of the medical instruments supplier’s stock worth $682,000 after purchasing an additional 777 shares in the last quarter.

Insider Buying and Selling

In other Insulet news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.47% of the stock is owned by insiders.

Insulet Stock Down 1.0 %

Insulet stock opened at $265.65 on Wednesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.77. The firm has a fifty day moving average price of $261.67 and a two-hundred day moving average price of $229.12. The firm has a market cap of $18.63 billion, a price-to-earnings ratio of 45.49, a P/E/G ratio of 4.12 and a beta of 1.22.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Wells Fargo & Company boosted their price objective on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Citigroup boosted their price target on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Raymond James increased their price objective on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. TD Cowen boosted their target price on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Finally, Barclays raised their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $272.81.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.